Clinical study of qingke pingchuan granules in treatment of light and common type of novel Coronavirus infection
Drugs and Clinic
; 38(2):437-441, 2023.
Article
in Chinese
| CAB Abstracts | ID: covidwho-2306538
ABSTRACT
Objective To observe the clinical efficacy and safety of Qingke Pingchuan Granules in treatment of light and common type of novel coronavirus infection(phlegm heat stagnating lung syndrome). Methods Sixty patients with novel coronavirus infection(phlegm heat stagnating lung syndrome) hospitalized in the Novel Coronavirus Unit of Shanghai Public Health Clinical Center from March 2022to June 2022 were selected and divided into control group and treatment group according to different therapeutic drugs, with 30 cases in each group. Patients in the control group were given conventional treatment. Patients in the treatment group were po administered with Qingke Pingchuan Granules on the basis of conventional treatment, 10 g/time, 3 times daily. The efficacy of TCM syndromes, inflammatory indexes and adverse reactions were observed before and after treatment. Results After treatment, the total effective rate in the treatment group(86.7%) was significantly higher than that in the control group(66.7%)(P < 0.05). After treatment, daytime and nighttime cough scores in 2 groups were lower than before treatment(P < 0.05), and daytime and nighttime cough scores in the treatment group were lower than those in the control group(P < 0.05). There was no significant difference in the levels of peripheral blood leukocytes and procalcitonin between the two groups before and after treatment. After treatment, the level of C-reactive protein(CRP) in the two groups was significantly lower than that before treatment(P < 0.05), and the CRP level in the treatment group was lower than that in the control group(P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion Qingke Pingchuan Granules has good clinical efficacy in treatment of light and common type of novel coronavirus infection(phlegm heat stagnating lung syndrome), and can relieve the clinical symptoms of patients, which has good safety.
Non-food/Non-feed Plant Products [SS200]; Prion; Viral; Bacterial and Fungal Pathogens of Humans [VV210]; Pharmacology [VV730]; human diseases; traditional Chinese medicines; herbal drugs; clinical trials; efficacy; safety; lungs; viral diseases; inflammation; adverse effects; cough; leukocytes; procalcitonin; C-reactive protein; symptoms; man; Coronaviridae; China; Homo; Hominidae; primates; mammals; vertebrates; Chordata; animals; eukaryotes; APEC countries; East Asia; Asia; high Human Development Index countries; upper-middle income countries; Nidovirales; positive-sense ssRNA Viruses; ssRNA Viruses; RNA Viruses; viruses; People's Republic of China; herbal medicines; viral infections; adverse reactions; leucocytes; white blood cells
Full text:
Available
Collection:
Databases of international organizations
Database:
CAB Abstracts
Type of study:
Prognostic study
Language:
Chinese
Journal:
Drugs and Clinic
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS